Kris on Oncology
Mark G. Kris, MD, is chief of the thoracic oncology service and the William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center in New York City, where he has been on staff since 1983. His research interests include targeted therapies for lung cancer, multimodality therapy, the development of new anticancer drugs, and symptom management with a focus on preventing emesis. In 2011, he received the ASCO Humanitarian Award.
+ Add to Email Alerts
+ Add to Email Alerts
- Rethinking Clinical Trial Design and Cure in NSCLC
- Call to Action: Prioritizing Cure in Lung Cancer
- 'We Need to Rethink Our Options': Lung Cancer Recurrence
- Neoadjuvant Bests Adjuvant Therapy in Lung Cancer
- Avoid Counseling Fatigue: 'Don't Give Up'
- Success in Clinical Trials: Putting Patients First
- Listen to Your Patients: Improving Antiemetic Regimens
- Toward a Cure: Chemotherapy Plus TKI in EGFR-Mutant NSCLC
- Community: Key to Keeping Up-to-Date in Thoracic Oncology
- Disappointing Sotorasib Results: How to Move Forward
- Open Medical Institute: Physicians Improving Patient Care
- Include Neoadjuvant Chemotherapy in Stage II-III Lung Cancer
- ASCO Insights: Impacts on Lung Cancer Care
- Unlikely Breakthrough of the Year: Chemo for Lung Cancer
- We're in a 'Brave New World' of Low-Grade Toxicities
- NSCLC: Case for Combining Chemo and Osimertinib
- How to Think About Second-Line Therapy in NSCLC
- Neoadjuvant Advantages: Treating Locally Advanced Lung Cancer
- Add Chemo for Fit Patients With EGFR-Mutant Lung Cancer
- New 'C Word': Cure Should Be Goal for Lung Cancer Patients